Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IASIS: AFIS for Gram-negative Pneumonia
NCT01969799Phase 2Completed
- Sponsor
- Cardeas Pharma Corp.
- Start
- Dec 2013
- Primary completion
- Mar 2016
- Modality
- Nanoparticles, Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of amikacin liposome inhalation suspension, fosfomycin in Gram-negative bacterial pneumonia, sponsored by Cardeas Pharma Corp.. Started Dec 2013; status: completed.
02
Drugs
amikacin liposome inhalation suspensionfosfomycin
03
Conditions
Gram-negative bacterial pneumonia
Beyond the preview
Go deeper on NCT01969799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01969799.